Rational engineering of semiconductor QDs enabling remarkable <sup>1</sup>O<sub>2</sub> production for tumor-targeted photodynamic therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28961533.
- Also identified by DOI 10.1016/j.biomaterials.2017.09.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Semiconductor quantum dots (QDs) have served as superior optically active nanomaterials for molecular imaging and photodynamic therapy (PDT), but the low singlet oxygen (<sup>1</sup>O<sub>2</sub>) quantum yield and lack of tumor selectivity have limited their applications for tumor PDT in vivo. Here, we report the rational engineering of QDs into tumor-targeting hybrid nanoparticles through micelle-encapsulating a pre-assembled unique QD-Zn-porphyrin complex, a highly fluorescent organic photosensitizer rhodamine 6G (R6G), and a near-infrared fluorophore NIR775 with folic acid labeled phospholipid polymers. These nanoparticles have large porphyrin payloads and strong light absorption capability, thus contributing to an extremely high <sup>1</sup>O<sub>2</sub> quantum yield (∼0.91) via an efficient dual energy transfer process. In vivo studies show that they can preferably accumulate in tumors through folate receptor-mediated active delivery, permitting non-invasive fluorescence imaging and effective PDT of tumors in living mice. This study highlights the utility of hybrid semiconductor QDs for both tumor imaging and PDT in vivo.
Medical subject headings
- Neoplasms
- Photochemotherapy
- Photosensitizing Agents
- Quantum Dots
- Singlet Oxygen